Related Experiment Video
Updated: Jul 5, 2026

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
Complete remission sustained 3 years from treatment initiation is a powerful surrogate for extended survival in
Bart Barlogie1, Elias Anaissie, Jeffrey Haessler
1Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, Arkansas 72205, USA. barlogiebart@uams.edu
Background:
Complete response (CR) has been considered a necessary although not sufficient early clinical endpoint for extended survival in multiple myeloma.
Methods:
By using Total Therapy 2 (TT2) clinical outcome data in 668 patients, whether sustained CR (SUS-CR) was potentially a superior surrogate for survival than attaining CR status per se was evaluated.
Results:
Compared with not achieving CR (NON-CR) and especially achieving and subsequently losing CR status (LOS-CR) within a 3-year landmark from treatment initiation, SUS-CR was associated with highly superior postlandmark survival (P < .0001). These results were validated in 231 untreated patients enrolled in the predecessor trial, TT1 (hazard ratio [HR] = 0.54, P = .013) and in 1103 previously treated patients on other transplant protocols (HR = 0.49; P < .001).
Conclusions:
In all 3 trial settings the survival benefit of SUS-CR was independent of metaphase abnormalities as a dominant adverse parameter. Given its bleak prognosis despite high CR rates, SUS-CR should be evaluated as a primary trial endpoint in high-risk myeloma.
Related Concept Videos
Treatment Resistent Cancers
Cancer Survival Analysis
Treatment Resistant Cancers
Kaplan-Meier Approach